XML 94 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions (Schedule of Unaudited Pro Forma Information) (Details) (Cadence Pharmaceuticals, Inc., Specialty Pharmaceuticals, USD $)
In Millions, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Jun. 27, 2014
Jun. 28, 2013
Jun. 27, 2014
Jun. 28, 2013
Cadence Pharmaceuticals, Inc. | Specialty Pharmaceuticals
       
Business Acquisition, Pro Forma Information [Line Items]        
Net sales, pro forma $ 653.1 $ 594.7 $ 1,816.8 $ 1,724.8
Net (loss) income, pro forma $ (18.2) $ (61.9) $ (20.8) $ (97.7)
Basic (loss) earnings per share, pro forma (in usd per share) $ (0.31) $ (1.07) $ (0.36) $ (1.69)
Diluted (loss) earnings per share, pro forma (in usd per share) $ (0.31) $ (1.07) $ (0.36) $ (1.69)